Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Aravis Ventures

Founders Jean-Philippe Tripet Simon Nebel

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 32
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 19
Rounds per year 1.45
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.41
Exits 10
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2001 was created Aravis Ventures, which is appeared as VC. The main office of represented VC is situated in the Zu00fcrich. The company was established in Europe in Switzerland.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Pharmaceutical. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Ikaria, Kalypsys, MerLion Pharma.

The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Aravis Ventures works on 3 percentage points more the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 9 percentage points more often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year. The higher amount of exits for fund were in 2015.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Aravis Ventures, startups are often financed by Novartis Venture Fund, 5AM Ventures, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, M Ventures, Dansk Innovation. In the next rounds fund is usually obtained by Novartis Venture Fund, Dansk Innovation, 5AM Ventures.

This organization was formed by Jean-Philippe Tripet, Simon Nebel. The overall number of key employees were 5.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Aravis Ventures:
Typical Co-investors
Aravis Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Aravis Ventures:

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Athelas

Biotechnology
Health Care
Life Science
$15M01 Feb 2019 Mountain View, California, United States

Bird Rock Bio

Biotechnology
Life Science
Therapeutics
$15M27 Mar 2014 San Diego, California, United States

Synaffix BV

Biotechnology
Therapeutics
18 Feb 2014 The Netherlands, North Brabant, Netherlands

Bellerophon Therapeutics

Biotechnology
Health Care
Medical
$80M26 Dec 2013 New Jersey, United States

Telormedix

Biopharma
Biotechnology
Health Care
Therapeutics
$7M02 Dec 2013 Ticino, Switzerland

Telormedix

Biopharma
Biotechnology
Health Care
Therapeutics
$6M25 Jan 2012 Ticino, Switzerland

Synosia Therapeutics

Biotechnology
Drug Discovery
Medical
Pharmaceuticals
Therapeutics
$30M12 Oct 2010 Basel, Basel-City, Switzerland

Biotechnology
Pharmaceutical
$7M11 Oct 2010 Central

Evolva

Biotechnology
Consulting
Food and Beverage
Health Care
Wellness
$17M11 Dec 2009 Aargau, Switzerland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Aravis Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 32
Average round size 21M
Rounds per year 1.45
Peak activity year 2009
Lead investments 7
Follow on index 0.41
Exits 10
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Athelas

Biotechnology
Health Care
Life Science
$15M01 Feb 2019 Mountain View, California, United States

Bird Rock Bio

Biotechnology
Life Science
Therapeutics
$15M27 Mar 2014 San Diego, California, United States

Synaffix BV

Biotechnology
Therapeutics
18 Feb 2014 The Netherlands, North Brabant, Netherlands

Bellerophon Therapeutics

Biotechnology
Health Care
Medical
$80M26 Dec 2013 New Jersey, United States

Telormedix

Biopharma
Biotechnology
Health Care
Therapeutics
$7M02 Dec 2013 Ticino, Switzerland

Telormedix

Biopharma
Biotechnology
Health Care
Therapeutics
$6M25 Jan 2012 Ticino, Switzerland

Synosia Therapeutics

Biotechnology
Drug Discovery
Medical
Pharmaceuticals
Therapeutics
$30M12 Oct 2010 Basel, Basel-City, Switzerland

Biotechnology
Pharmaceutical
$7M11 Oct 2010 Central

Evolva

Biotechnology
Consulting
Food and Beverage
Health Care
Wellness
$17M11 Dec 2009 Aargau, Switzerland
Crunchbase icon

Content report

The following text will be sent to our editors: